EU: Irhythm Technologies (IRTC) Stock Has Just Had Its “Buy” Rating Reiterated by Canaccord Genuity. Shares now Have a $80.0000 Target

May 18, 2018 - By Bradley Stiles

Irhythm Technologies (IRTC) Rating Reaffirmed

In analysts note published this morning, Canaccord Genuity maintained their “Buy” rating on Irhythm Technologies (IRTC) shares. The target gives a possible upside of 17.35 % from firm’s previous close.

iRhythm Technologies, Inc. (NASDAQ:IRTC) Ratings Coverage

Among 5 analysts covering iRhythm Technologies (IRTC), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. iRhythm Technologies has $80 highest and $60.0 lowest target. $72’s average target is 5.62% above currents $68.17 stock price. iRhythm Technologies had 8 analyst reports since December 4, 2017 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, February 14 report. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, January 3 report. JP Morgan maintained iRhythm Technologies, Inc. (NASDAQ:IRTC) rating on Thursday, February 15. JP Morgan has “Overweight” rating and $67 target. The stock of iRhythm Technologies, Inc. (NASDAQ:IRTC) has “Buy” rating given on Thursday, May 3 by Canaccord Genuity. Canaccord Genuity maintained iRhythm Technologies, Inc. (NASDAQ:IRTC) on Monday, March 12 with “Buy” rating. The stock has “Hold” rating by Northland Capital on Monday, March 12.

The stock increased 0.53% or $0.36 during the last trading session, reaching $68.17. About 247,996 shares traded or 17.00% up from the average. iRhythm Technologies, Inc. (IRTC) has risen 69.09% since May 18, 2017 and is uptrending. It has outperformed by 57.54% the S&P500.

Analysts await iRhythm Technologies, Inc. (NASDAQ:IRTC) to report earnings on August, 1. They expect $-0.41 earnings per share, down 41.38 % or $0.12 from last year’s $-0.29 per share. After $-0.47 actual earnings per share reported by iRhythm Technologies, Inc. for the previous quarter, Wall Street now forecasts -12.77 % EPS growth.

iRhythm Technologies, Inc., a digital healthcare company, focuses on the provision of ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias in the United States. The company has market cap of $1.61 billion. It offers ZIO Service, a platform that provides wearable biosensor with cloud data analytics that distill data from heartbeats into clinically actionable information. It currently has negative earnings.

More notable recent iRhythm Technologies, Inc. (NASDAQ:IRTC) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” on May 10, 2018, also Globenewswire.com with their article: “iRhythm Technologies Announces First Quarter Financial Results” published on May 02, 2018, Streetinsider.com published: “Lakewood Capital Sees 70% Downside in iRhythm Technologies (IRTC)” on April 24, 2018. More interesting news about iRhythm Technologies, Inc. (NASDAQ:IRTC) were released by: Seekingalpha.com and their article: “Real-world study supports value proposition of iRhythm’s Zio” published on May 16, 2018 as well as Streetinsider.com‘s news article titled: “iRhythm Technologies (IRTC) Says JAMA Cardiology published RHYTHM Study Revealing Link Between Total AF …” with publication date: May 16, 2018.

iRhythm Technologies, Inc. (NASDAQ:IRTC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: